Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Summit Therapeutics (SMMT) stock

Learn how to easily invest in Summit Therapeutics stock.

Summit Therapeutics Inc
-$0.06 (-0.79%)

Summit Therapeutics Inc is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Summit Therapeutics employs 79 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Summit Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SMMT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Summit Therapeutics stock price (NASDAQ: SMMT)

Use our graph to track the performance of SMMT stocks over time.

Summit Therapeutics shares at a glance

Information last updated 2021-07-22.
Latest market close$7.82
52-week range$3.14 - $10.99
50-day moving average $7.18
200-day moving average $6.60
Wall St. target price$4.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $1.23

Buy Summit Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Summit Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Summit Therapeutics price performance over time

Historical closes compared with the close of $7.82 from 2021-05-28

1 week (2021-07-17) N/A
1 month (2021-06-28) 9.37%
3 months (2021-04-28) 23.34%
6 months (2021-01-24) N/A
1 year (2020-07-24) N/A
2 years (2019-07-24) N/A
3 years (2018-07-24) N/A
5 years (2016-07-24) N/A

Summit Therapeutics financials

Revenue TTM $728,000
Gross profit TTM $860,000
Return on assets TTM -32.54%
Return on equity TTM -96.82%
Profit margin 0%
Book value $0.78
Market capitalisation $771.1 million

TTM: trailing 12 months

Shorting Summit Therapeutics shares

There are currently 810,542 Summit Therapeutics shares held short by investors – that's known as Summit Therapeutics's "short interest". This figure is 104.5% up from 396,260 last month.

There are a few different ways that this level of interest in shorting Summit Therapeutics shares can be evaluated.

Summit Therapeutics's "short interest ratio" (SIR)

Summit Therapeutics's "short interest ratio" (SIR) is the quantity of Summit Therapeutics shares currently shorted divided by the average quantity of Summit Therapeutics shares traded daily (recently around 371808.25688073). Summit Therapeutics's SIR currently stands at 2.18. In other words for every 100,000 Summit Therapeutics shares traded daily on the market, roughly 2180 shares are currently held short.

However Summit Therapeutics's short interest can also be evaluated against the total number of Summit Therapeutics shares, or, against the total number of tradable Summit Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Summit Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Summit Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0329% of the tradable shares (for every 100,000 tradable Summit Therapeutics shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Summit Therapeutics.

Find out more about how you can short Summit Therapeutics stock.

Summit Therapeutics share dividends

We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.

Summit Therapeutics share price volatility

Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $3.14 up to $10.99. A popular way to gauge a stock's volatility is its "beta".

SMMT.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is 0.6175. This would suggest that Summit Therapeutics's shares are less volatile than average (for this exchange).

Summit Therapeutics overview

Summit Therapeutics Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts. .

Stocks similar to Summit Therapeutics

Frequently asked questions

What percentage of Summit Therapeutics is owned by insiders or institutions?
Currently 74.078% of Summit Therapeutics shares are held by insiders and 9.762% by institutions.
How many people work for Summit Therapeutics?
Latest data suggests 79 work at Summit Therapeutics.
When does the fiscal year end for Summit Therapeutics?
Summit Therapeutics's fiscal year ends in January.
Where is Summit Therapeutics based?
Summit Therapeutics's address is: One Broadway, Cambridge, MA, United States, 02142
What is Summit Therapeutics's ISIN number?
Summit Therapeutics's international securities identification number is: US86627T1088
What is Summit Therapeutics's CUSIP number?
Summit Therapeutics's Committee on Uniform Securities Identification Procedures number is: 86627R102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site